Investors & Media

Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome

ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients ION582 was safe and well tolerated at all dose levels Ionis plans to move ION582 into pivotal trial Detailed ION582 data to be presented at upcoming medical meeting CARLSBAD, Calif.

Read more
You are now leaving https://www.ionispharma.com to visit